For example, gene expression-based RB1 loss signatures have been shown to be prognostic across cancer types (but have not been assessed regarding drug response)49, and Ras-pathway activation signatures have been shown to predict MEK inhibitor sensitivity50. This evidence concerns the gene RB1 and cancer.